http://www.ncbi.nlm.nih.gov/myncbi/browse/collection/49405356/?sort=date&direction=descending
2024
Singh D, Qiu Z, Jonathan SM, Fa P, Thomas H, Prasad CB, Cai S, Wang JJ, Yan C, Zhang X, Venere M, Li Z, Sizemore ST, Wang QE, Zhang J. PP2A B55α inhibits epithelial-mesenchymal transition via regulation of Slug expression in non-small cell lung cancer. Cancer Lett, Jul 8;598:217110. 2024.
Youssef G, Acquaye-Mallory A, Vera E, Chheda MG, Dunn GP, Moliterno J, O’Brien BJ, Venere M, Yust-Katz S, Lee EQ, Armstrong TS. Burnout and career satisfaction in young neuro-oncology investigators: Results of the Society for Neuro-Oncology Young Investigator Survey. Neurooncol Pract, Mar 13;11(4):494-506, 2024.
2023
Rist D, DePalma T, Stagner E, Tallman MM, Venere M, Skardal A, Schultz ZD. Cancer Cell Targeting, Magnetic Sorting, and SERS Detection through Cell Surface Receptors. ACS Sens, Dec 22;8(12):4636-4645. 2023.
Summers MK, Venere M. Walking the tightrope between DNA damage repair and genomic integrity. Neuro Oncol, Nov 14. Online ahead of print. 2023.
Singh K, Han C, Fleming JL, Becker AP, McElroy J, Cui T, Johnson B, Kumar A, Sebastian E, Showalter CA, Schrock MS, Summers MK, Becker V, Tong ZY, Meng X, Manring HR, Venere M, Bell EH, Robe PA, Grosu AL, Haque SJ, Chakravarti A. TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathways. Sci Rep, Aug 1;13(1):12424. 2023.
Corrales-Guerrero S, Cui T, Castro-Aceituno V, Yang L, Nair S, Feng H, Venere M, Yoon S, DeWees T, Shen C, Williams TM. Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1. Cancer Lett, Aug 28;570. 2023.
Tallman MM, Zalenski AA, Stabl I, Schrock MS, Kollin L, de Jong E, De K, Grubb TM, Summers MK, Venere M. Improving localized radiotherapy for glioblastoma via small molecule inhibition of KIF11. Cancers, Jun 13;15(12):3173. 2023.
Schrock MS, Zalenski AA, Tallman MM, Kollin L, Bratasz A, Weeks G, Miller MA, Sweeney CN, Pluhar GE, Olin MR, Kisseberth WC, Bentley RT, Dickinson PJ, York D, Webb A, Wang X, Moore S, Venere M, Summers MK. Establishment and characterization of two novel patient-derived lines from canine high-grade glioma. Vet Comp Oncol, Sep;21(3):492-502. 2023.
Che J, DePalma TJ, Sivakumar H, Mezache LS, Tallman MM, Venere M, Swindle-Reilly K, Veeraraghavan R, Skardal A. αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform. Biotechnol Bioeng, Apr;120(4):1108-1119. 2023.
2022
Cai S, Li N, Bai X, Liu L, Banerjee A, Lavudi K, Zhang X, Zhao J, Venere M, Duan W, Zhang J, Welliver MX, He K, Wang Q. ERK inactivation enhances stemness of NSCLC cells via promoting Slug-mediated epithelial-to-mesenchymal transition. Theranostics, Oct 3;12(16):7051-7066. 2022.
Broestl L, Warrington NM, Grandison L, Abou-Antoun T, Tung O, Shenoy S, Tallman MM, Rhee G, Yang W, Sponagel J, Yang L, Kfoury-Beaumont N, Hill CM, Qanni SA, Mao DD, Kim AH, Stewart SA, Venere M, Luo J, Rubin JB. Gonadal sex patterns p21-induced cellular senescence in mouse and human glioblastoma. Commun Biol, Aug 2;5(1):781. 2022.
2021
Venere M, Lathia JD. All damage is not created equal: unraveling the complexity of sex chromosomes and hormones in the DNA damage response. Endocrinology, Dec 1;162(12):bqab213, 2021.
Zalenski AA, Venere M. Capitalizing on ATRX loss in glioma via PARP inhibition: Comment on “Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity” by Garbarino et al. Transl Oncol, Sep;14(9):101173, 2021.
Zalenski AA, Tallman, MM, Venere M. Stem cell based modelling of glioblastoma. In Precision Molecular Pathology of Glioblastoma. Otero JJ, Becker AP (Eds). Springer Science, New York, New York. 2021.
Tallman MM, Zalenski AA, Deighen AM, Schrock MS, Mortach S, Grubb TM, Kastury PS, Huntoon K, Summers MK, Venere M. The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma. Cancer Lett, Feb 28;499:232-242. 2021.
Cui T, Bell EH, McElroy J, Liu K, Sebastian E, Johnson B, Gulati PM, Becker AP, Gray A, Geurts M, Subedi D, Yang L, Fleming J, Meng W, Barnholtz-Sloan JS, Venere M, Wang QE, Robe PA, Haque SJ, Chakravarti A. A novel miR-146a-POU3F2/SMARCA5 pathway regulates stemness and therapeutic response in glioblastoma. Mol Cancer Res, Jan;19(1):48-60. 2021.
2020
Zalenski AA, Majumder S, De K, Venere M. An interphase pool of KIF11 localizes at the basal bodies of primary cilia and a reduction in KIF11 expression alters cilia dynamics. Sci Rep, Aug 18;10(1):13946. 2020.
Pal D, Torres AE, Stromberg BR, Messina AL, Dickson AS, De K, Willard B, Venere M, Summers MK. Chk1-mediated Phosphorylation of Cdh1 Promotes the SCF βTRCP-dependent Degradation of Cdh1 During S-phase and Efficient Cell-Cycle Progression. Cell Death Dis, Apr;11(4):298. 2020.
Zalenski AA, Tallman, MM, Venere M. Stem cell based modelling of glioblastoma. In Precision Molecular Pathology of Glioblastoma. Otero JJ, Becker AP (Eds). Springer Science, New York, New York. 2020.
Balogun J, Haynes C, Lwin Z, Nduom E, Puduvalli V, Venere M, Zadeh G. Providing a Global Platform for Communication and Exchange in Neuro-Oncology. Neuro Oncol, Nov 26;22(11):1551-1552, 2020.
Venere M, Zadeh G, Puduvalli V, Haynes C. SNO 25th anniversary history series: Ancillary and satellite meetings of the Society for Neuro-Oncology. Neuro Oncol, Sep 29;22(9):1231-1232, 2020.
Puduvalli V, Venere M, Haynes C, Zadeh G. SNO 25th anniversary history series: The SNO Annual Meeting – A nexus for science, collaboration and community. Neuro Oncol, Aug 17;22(8):1053-1055, 2020.
Venere M, Zadeh G, Puduvalli V, Haynes C. Investing in the Membership of the Society for Neuro-Oncology. Neuro Oncol, July 7;22(7):897-898, 2020.
Venere M, Zadeh G, Puduvalli V, Haynes C. SNO 25th Anniversary History Series: Spotlight on Neuro-Oncology Practice and Neuro-Oncology Advances. Neuro Oncol, June 9;22(6):739-740, 2020.
Venere M, Zadeh G, Puduvalli V, Haynes C. Celebrating SNO’s Official Journal, Neuro-Oncology. Neuro Oncol, May 15;22(5):585-586, 2020.
Venere M, Zadeh G, Puduvalli V, Haynes C. The Society for Neuro-Oncology: 20/20 Vision for the Future. Neuro Oncol, Apr 15;22(4):435-436, 2020.
2019
Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, Eberhart CG, Brat DJ, Sarkaria JN. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro Oncol, Dec 17;21(12):1498-1508, 2019.
De K, Grubb TM, Zalenski AA, Pfaff KE, Pal D, Majumder S, Summers MK, Venere M. Hyperphosphorylation of CDH1 in glioblastoma cancer stem cells attenuates APC/CCDH1 activity and pharmacological inhibition of APC/CCDH1/CDC20 compromises viability. Mol Cancer Res, Jul;17(7):1519-1530. 2019.
Park JK, Kim J, Testoff T, Adams J, Poklar M, Zborowski M, Venere M*, Chalmers JJ*. Quantitative Characterization of the Regulation of Iron Metabolism in Glioblastoma Stem-Like Cells using Magnetophoresis. Biotechnol Bioeng, Jul;116(7):1644-1655, 2019. *co-corresponding authors
Taylor JW, Armstrong T, Kim AH, Venere M, Acquaye A, Schrag D, Wen PY. The lomustine crisis: awareness and impact of the 1500% price hike. Neuro Oncol, Jan 1;21(1):1-3, 2019.
2018
Jarrar A, Lotti F, DeVecchio J, Ferrandon S, Gantt G, Mace A, Karagkounis G, Orloff M, Venere M, Hitomi M, Lathia J, Rich JN, Kalady MF. Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy. Stem Cells, Jan;37(1):42-53, 2018.
Sharma A, Alswillah T, Singh K, Chatterjee P, Willard B, Venere M, Summers MK, Almasan A. USP14 regulates DNA damage repair by targeting RNF168-dependent ubiquitination. Autophagy, Aug 10:1-15, 2018.
Muretta JM, Reddy BJN, Scarabelli G, Thompson AF, Jariwala S, Major J, Venere M, Rich JN, Willard B, Thomas DD, Stumpff J, Grant BJ, Gross SP, Rosenfeld SS. A posttranslational modification of the mitotic kinesin Eg5 that enhances its mechanochemical coupling and alters its mitotic function. Proc Natl Acad Sci, Feb 20;115(8):E1779-E1788, 2018.
Venere M, De K, Yoo JY, Kaur B. Apoptosis Pathways and Chemotherapy in Brain Tumors. In: Newton HB, ed. Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, Second Edition. San Diego: Academic Press, 291-303, 2018.
2017
Zalenski A, De K, Venere M. Not just another biomarker: the role of integrin alpha 7 in glioblastoma. Stem Cell Investig, Dec 20;4:99, 2017.
Venere M. Personalized medicine finds the MAPK for breast cancer. Sci Transl Med, 9(421), 2017.
Venere M. Serving cancer its last meal. Sci Transl Med, 9(415), 2017.
Venere M. Foe becomes friend as Zika joins the fight against cancer. Sci Transl Med, 9(409), 2017.
Venere M. Prostate cancer loses when androgen receptor can’t stick the landing. Sci Transl Med, 9(403), 2017.
Venere M. Self-tanning cells, the new SPF. Sci Transl Med, 9(397), 2017.
Venere M. A GEMA of a personalized medicine strategy. Sci Transl Med, 9(391), 2017.
Venere M. Getting down to the FACT: therapeutic targeting of MYC-dependent tumors. Ann Transl Med, 5(7):174, 2017.
Venere M. Vitamin C puts the pedal to the metal. Sci Transl Med, 9(385), 2017.
Venere M. Astrocytes light up glial heterogeneity. Sci Transl Med, 9(379), 2017.
2016
Godek K, Venere M, Wu Q, Mills K, Hickey W, Rich J, and Compton D. Chromosomal instability affects the tumorigenicity of glioblastoma tumor-initiating cells. Cancer Discov, 6(5):532-45, 2016.
Dermawan JKT, Hitomi M, DJ, Qiulian Wu, Sandlesh P, Sloan AE, Purmal AA, Gurova KV, Rich JN, Lathia JD, Stark GR*, Venere M*. Pharmacological targeting of the histone chaperone complex FACT preferentially eliminates glioblastoma stem cells and prolongs survival in preclinical models. Cancer Res, 15;76(8):2432-42, 2016. *co-corresponding authors
Articles prior to starting the Venere Lab at OSU
2015
Adorno-Cruz V, Golam Kibria G, Liu X, Doherty M, Junk D, Guan D, Hubert C, Venere M, Mulkearns-Hubert E, Sinyuk M, Alvarado A, Caplan AI, Rich J, Gerson SL, Lathia J, Liu H. Cancer Stem Cells: Targeting the Roots of Cancer, Seeds of Metastasis, and Sources of Therapy Resistance. Cancer Res, 75(6):924-9, 2015.
Venere M, Horbinski CM, Crish JF, Jin X, Vasanji A, Major J, Burrows A, Chang C, Prokop J, Wu Q, Sims PA, Canoll P, Summers MK, Rosenfeld SS, Rich JN. The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self renewal in glioblastoma. Sci Transl Med, Sep 9:7(304), 2015. Featured in Neuro-Oncology, Highlights in the Literature, contributed by Abounader R, Bhat K, Soffietti R, and Lowler S, edited by Aldape K, 17(12): 1547-1549, 2015.
2014
Venere M, Hamerlik P, Wu Q, Rasmussen RD, Song LA, Vasanji A, Tenley N, Flavahan WA, Hjelmeland AB, Bartek J, Rich JN. Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma initiating cells. Cell Death Differ, 21(2):258-269, 2014. Editorial by Lugli, Kamileri and Halazonetis. Cell Death Differ, 21(2):192-193, 2014.
2013
Date DA, Burrows AC, Venere M, Jackson MW, Summers MK. Coordinated regulation of p31Comet and Mad2 expression is required for cellular proliferation. Cell Cycle, 12(24):3824-32, 2013.
Schonberg DL, Venere M, Rich JN. Changing the fate of cancer, one splice at a time. Proc Natl Acad Sci, 110(36):14510-1, 2013.
Venere M, Lathia JD, Rich JN. Growth factor receptors define cancer hierarchies. Cancer Cell, 11;23(2):135-7, 2013.
Venere M, Miller TE, Rich JN. Mitotic Control of Cancer Stem Cells. Cancer Discovery, 3(2):141-4. 2013.
Venere M, Rich JN, Bao S. DNA repair mechanisms in glioblastoma cancer stem cells, in Mathews LA, et al. (eds.): DNA repair of cancer stem cells. New York, NY. Springer Science, 2013.
2012
Venere M, Han YG, Song JS, Bell R, Alvarez-Buylla A, Blelloch R. Sox1 marks an activated neural stem/progenitor cell of the hippocampus. Development, 139(21):3938-49, 2012.
Lathia JD, Gallagher J, Hall PE, Li M, Levy E, Venere M, Rani MS, Huang P, Cheng L, McLendon RE, Sloan AE, Bao S, Gladson C, Bredel M, Hjelmeland AB, Rich JN. Laminin alpha 2 enables glioblastoma stem cell growth. Ann Neurol, 72(5):766-78, 2012.
2011
Heddleston JM, Hitomi M, Venere M, Flavahan WA, Yang K, Kim Y, Minhas S, Rich JN, Hjelmeland AB. Glioma stem cell maintenance: the role of the microenvironment. Curr Pharm Des, 17(23):2386-401, 2011.
Lathia JD, Heddleston JM, Venere M, Rich JN. Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell, 8(5):482-5, 2011.
Venere M*, Fine HA, Dirks PB, Rich JN. Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer’s hierarchy. Glia, 59(8):1148-54, 2011. *corresponding author
Lathia JD, Venere M, Rao MS, Rich JN. Seeing is believing: are cancer stem cells the Loch Ness monster of tumor biology? Stem Cell Rev, 7(2):227-37, 2011.
2010
Mayers CM, Wadell J, McLean K, Venere M, Malik M, Shibata T, Driggers PH, Kino T, Guo XC, Koide H, Gorivodsky M, Grinberg A, Mukhopadhyay M, Abu-Asab M, Westphal H, Segars JH. The Rho guanine nucleotide exchange factor AKAP13 (BRX) is essential for cardiac development in mice. J Biol Chem, 285(16):12344-54, 2010.
2009
Judson RL, Babiarz J, Venere M, Blelloch R. Embryonic stem cell specific microRNAs promote induced pluripotency. Nat Biotech, 27(5):459-61, 2009.
2007
Blelloch R, Venere M, Yen J, Ramalho-Santos M. Generation of induced pluripotent stem cells in the absence of drug selection. Cell Stem Cell, 1(3):245-7, 2007.
Venere M, Snyder A, Zgheib O, Halazonetis TD. Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function. Cancer Res, 1;67(13):6100-5, 2007.
Tsimaratou K, Kletsas D, Kastrinakis NG, Tsantoulis PK, Evangelou K, Sideridou M, Liontos M, Poulias I, Venere M, Salmas M, Kittas C, Halazonetis TD, Gorgoulis VG. Evaluation of claspin as a proliferation marker in human cancer and normal tissues. J Pathol, 211(3):331-9, 2007.
2006
Peschiaroli A, Dorrello NV, Guardavaccaro D, Venere M, Halazonetis TD, Sherman NE, Pagano M. SCFβTrCP-Mediated Degradation of Claspin Regulates Recovery from the DNA Replication Checkpoint Response. Mol Cell, 23(3):319-329, 2006.
2005
Livingstone M, Ruan H, Weiner J, Clauser KR, Strack P, Jin S, Williams A, Greulich H, Gardner J, Venere M, Mochan TA, DiTullio RA Jr, Moravcevic K, Gorgoulis VG, Burkhardt A, Halazonetis TD. Valosin-containing protein phosphorylation at Ser784 in response to DNA damage. Cancer Res, 65(17):7533-40, 2005.
Zgheib O, Huyen Y, Ditullio RA Jr, Snyder A, Venere M, Stravridi ES, Halazonetis TD. ATM signaling and 53BP1. Radiother Oncol, 76(2):119-22, 2005.
2004
Gorgoulis VG, Vassiliou1 LV, Karakaidos1 P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, DiTullio RA Jr, Kastrinakis1 NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD. Activation of the DNA damage checkpoint is an early event in the natural history of human cancer. Nature, 434:907-913, 2004.
MacPherson D, Kim J, Kim T, Rhee BK, Van Oostrom CT, DiTullio RA Jr, Venere M, Halazonetis TD, Bronson R, De Vries A, Fleming M, Jacks T. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J, 23(18):3689-99, 2004.
Mochan TA, Venere M, DiTullio RA Jr, Halazonetis TD. 53BP1, an activator of ATM in response to DNA damage. DNA Repair, 3(8-9):945-52, 2004.
2003
Mochan TA, Venere M, DiTullio RA Jr, Halazonetis TD. 53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res, 63(24):8586-91, 2003.
Bothos J, Summers MK, Venere M, Scolnick DM, Halazonetis TD. The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chains. Oncogene, 22(46):7101-7, 2003.
2002
DiTullio RA Jr., Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J, Halazonetis TD. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol, 4(12):998-1002, 2002.
Venere M, Mochan TA, Halazonetis TD. Chk2 leaves the PML depot. Nat Cell Biol, 4(11):E255-6, 2002.